Invivyd Names Marc Elia CEO Ahead Of VYD2311 Phase 3 COVID Readout
Jonathan Blake
Coverage
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Latest
Ionis Wins FDA Approval For Zanvastro In Alexander Disease, Opening Its First Independent Neurology Launch
Emily Carter
Pfizer Transfers PF-08046031 To Medicus In Up To $1B-Plus Deal, Extending Seagen Asset Recycling
Daniel Cho
GSK Bets Up To $1.295 Billion On Hutchmed’s HMPL-A830, Extending Its Asia Deal Push
Daniel Cho
Most read
Novartis Signs Up To $3.2 Billion Alteogen Deal, Expanding Its Subcutaneous Delivery Options
Michael Torres
Takeda And Protagonist Win Mimrylo Approval In Polycythemia Vera, Opening A Broader-Than-Expected Launch
Dr. Priya Nandakumar
Roche Strikes Up To $1.53 Billion Simcere Deal For SIM0660, Extending Its Asia Licensing Run
Daniel Cho
BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer
Dr. Priya Nandakumar
More in this beat
Sep 3, 2026Fortrea Buys Worldwide Early-Phase Unit For $45 Million, Expanding Texas Capacity
Fortrea said the acquisition will bring Worldwide’s clinical pharmacology unit and bioanalytical laboratory operations into its clinical pharmacology services business unit. The transaction is aimed at adding early-phase capacity and reducing handoffs between clinical and bioanalytical functions, while Worldwide plans to use the proceeds to support its late-stage focus areas.
Dr. Priya NandakumarSep 2, 2026Novartis Signs Up To $3.2 Billion Alteogen Deal, Expanding Its Subcutaneous Delivery Options
Alteogen said Novartis will hold multiple options to secure exclusive rights to develop drugs using ALT-B4, though the release did not disclose an upfront fee. The agreement extends a run of partnerings that has turned the Korean company into one of the main challengers to Halozyme Therapeutics in subcutaneous drug delivery.
Michael Torres
Sep 2, 2026ArsenalBio Cuts 99 Jobs In Pivot To In Vivo CAR-T, Halting Ex Vivo Clinical Development
Arsenal Biosciences said a "significant strategic shift" will leave it with a core team focused on in vivo CAR-T therapies. At the same time, the company is seeking strategic opportunities for its existing technology and assets after dropping prior lead programs from its pipeline.
Dr. Priya NandakumarSep 1, 2026Roche Strikes Up To $1.53 Billion Simcere Deal For SIM0660, Extending Its Asia Licensing Run
SIM0660 targets CD79a, CD19 and CD3 and is being positioned around B-cell-mediated diseases, including certain lymphomas, with Roche saying the collaboration will focus on malignancies. The deal also adds to a growing pattern of Chinese biotechs using out-licensing to monetize early assets before late-stage development.
Daniel Cho
Sep 1, 2026GSK Starts Phase 3 For FLUm3HA.b-3NA After Phase 2 Flu Immunogenicity Win, Seeking A Stronger mRNA Entry
The update gives GSK a new shot at rebuilding a flu vaccine business that shrank by about 25% last year amid competitive pressure in the U.S. It also sharpens the next competitive question in mRNA flu: whether adding neuraminidase to the antigen mix can improve on first-generation products that focus mainly on hemagglutinin.
Dr. Priya NandakumarSep 1, 2026Takeda And Protagonist Win Mimrylo Approval In Polycythemia Vera, Opening A Broader-Than-Expected Launch
Takeda’s latest approval adds a second recent launch to what Jefferies described as the company’s next growth cycle. For Mimrylo, the commercial signal is less the approval itself than the scope of the label, which Jefferies said does not require prior treatment with medications that lower blood cell counts.
Dr. Priya Nandakumar
Sep 1, 2026Eli Lilly Strikes Up To $2.875 Billion Merida Deal, Extending Its Autoantibody Strategy In Immunology
Lilly said it will pay up to $2.875 billion, including an upfront payment and contingent milestones, to buy Merida Biosciences, with closing expected in the fourth quarter pending clearances. The acquisition adds MER511 in Phase 1 for thyroid eye disease and Graves’ disease, MER769 in preclinical development for allergic conditions, and a platform designed to selectively target and destroy disease-causing autoantibodies.
Daniel ChoAug 29, 2026BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer
The stopped study tested whether autogene cevumeran, also known as BNT122, could prevent recurrence after surgery by targeting each patient’s tumor mutations. Instead, Genentech confirmed there were more deaths in the vaccine arm in this patient population, shifting attention to whether the platform’s future depends on combination use rather than standalone treatment.
Dr. Priya Nandakumar
Aug 29, 2026Wainua Phase 3 Setback Clouds TTR Silencers, Strengthening The Case For ATTR-CM Stabilizers
AstraZeneca and Ionis Pharmaceuticals’ Wainua posted a hazard ratio of 1.14 in ATTR-CM when given alongside standard of care treatment, a result that Stifel called clearly worse than expected. While monotherapy data showed a 29% improvement in cardiovascular events, the combined picture makes a regulatory path harder to see and may influence how rivals position next-generation programs.
Jonathan Blake
Aug 28, 2026Teva Sets $57.5 Million Floor For BioXcel Assets, Tying More Value To BXCL501 FDA Timing
BioXcel moved into bankruptcy after warning it lacked funds to operate through the end of August, even after securing a loan earlier this week. Teva’s bid includes $57.5 million upfront and up to $67.5 million in milestones, with the largest payout contingent on BXCL501 winning approval by the current Nov. 14 PDUFA date.
Emily Carter
Aug 28, 2026AstraZeneca And Amgen Post Tezspire EoE Phase 3 Win, Opening A Dosing-Based Challenge To Dupixent
AstraZeneca and Amgen reported that Tezspire significantly improved histologic remission and dysphagia symptoms at 24 weeks in the Phase 3 CROSSING study, with effects sustained through 52 weeks. The announcement matters because Dupixent currently owns the biologic category in eosinophilic esophagitis, yet Tezspire may have a practical differentiator in dosing frequency if the full efficacy data are competitive.
Michael Torres
Aug 28, 2026Roivant Wins Lisraya Approval In Dermatomyositis, Adding A Once-Daily Pill For A Rare Autoimmune Disease
The drug will be sold as Lisraya and taken once daily. For Roivant, the approval turns a rare-disease immunology program into a commercial product in a U.S. market the company says includes between 40,000 and 70,000 people.
Michael TorresOther beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.